Stock Price Forecast

March 25, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Soligenix Inc chart...

About the Company

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

$0M

Total Revenue

23

Employees

$6M

Market Capitalization

-0.21

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SNGX News

Soligenix Inc.

6d ago, source: TheStreet.com

SOLIGENIX INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net ...

Why Is This Rare Disease-Focused Soligenix Stock Trading Over 200% Today?

3mon ago, source: Hosted on MSN

The FDA has cleared Soligenix Inc's (NASDAQ: SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers in Behçet's disease.

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

13d ago, source: Nasdaq

As of December 31, 2023, the Company's cash position was approximately $8.4 million. About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and ...

Why Are Soligenix Shares Trading Higher Today

10mon ago, source: Hosted on MSN

Soligenix Inc (NASDAQ: SNGX) released clinical results from a compatibility study evaluating HyBryte for cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible ...

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

1mon ago, source: Nasdaq

PRINCETON, N.J., Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

6d ago, source: ADVFN

PRINCETON, N.J., Nov. 30, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Soligenix, Inc.

6mon ago, source: CNN

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized ...

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

13d ago, source: Morningstar

PRINCETON, N.J., March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

13d ago, source:

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

SOLIGENIX, INC.: Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

13d ago, source:

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...